Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan vs Melphalan Conditioning in AML and MDS
NCT07025824Phase 2Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Jan 2026
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Technische Universität Dresden. Started Jan 2026; status: recruiting.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07025824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025824.